Novartis receives approval for first malaria medicine for newborn babies and young infants
Novartis announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease. Eight African countries also participated in the assessment and Read More




